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Abstract
Background: In the psychiatric acute and emergency services patients present in severe crisis often complicated
by behavioral problems, substance use, and multiple axis 1 diagnoses. In these clinical settings both legal and
illegal use of benzodiazepines are difficult to evaluate since benzodiazepines could in some patients be regarded
as first line treatment and in other patients as the cause of the acute psychiatric condition. The aims of this study
were to evaluate the frequency and clinical effects of both legal and illegal use of benzodiazepines at admittance
to a psychiatric acute department.
Methods: All patients acutely admitted to a Norwegian acute psychiatric university department serving a
catchment area were asked about use of benzodiazepines, other medications and substances before admission.
Patients were asked to give urine samples for analyses of benzodiazepines and substances.
Results: In 227 consecutive admissions there was legal use of benzodiazepines before admission in 39%, illegal use
in 13% and no use in 48%. Patients with legal use of benzodiazepines were older, used more often antidepressants
and a higher number of prescribed psychotropic medications. Illegal users of benzodiazepines more often used
other illegal substances, were evaluated as clinically affected by a substance at admittance and were diagnosed
with a substance use disorder. Patients with psychoses or major affective disorders treated with adequate
medication (antidepressants, antipsychotics or mood-stabilizers) before admission more often received
benzodiazepines than patients without adequate medication.
Conclusions: The patients using benzodiazepines at admittance to psychiatric acute departments could be divided
in illegal and legal users. The illegal users were young, used illegal substances and were more often regarded
clinically affected by substances at admittance. The legal users were older, did not use other substances and were
not regarded as clinically affected by substances at admittance. Benzodiazepines were used as adjuvant therapy to
specific pharmacological treatment with antidepressants, antipsychotics or mood stabilizers for major psychiatric
disorders.
Trial registration: NCT 00184119/NCT 00184132.
Background
Use and abuse of benzodiazepines are difficult to evalu-
ate in psychiatric acute admissions. Patients present in
severe crisis often complicated by behavioral problems,
substance use, and multiple axis 1 diagnoses [1]. In
these clinical settings benzodiazepines are regarded as
first line nonspecific treatment in patients suffering
from acute agitated and psychotic conditions without
known cause [2], and specific treatment in patients suf-
fering from acute catatonia [3]. In patients suffering
from severe agitation and substance abuse, benzodiaze-
pines may also be regarded as first line acute treatment
[4]. A substantial number of other patients suffering
from psychoses or major depressive disorders use ben-
zodiazepines as adjuvant symptomatic treatment to anti-
psychotics, mood stabilizers or antidepressants [2,5,6].
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zepines for years without being treated with antidepres-
sants [7-9].
Medication with benzodiazepines may have short and
long time negative consequences. Frequently patients
are admitted to psychiatric acute departments due to
abstinence, intoxication, delirium and seizures [10]. Ben-
zodiazepines are also abused in combination with illegal
substances. Such abuse as part of a major psychiatric
disorder is probably frequent [7].
Benzodiazepine use has been found in 40 to 45% of
patients admitted to psychiatric hospitals [11-15], and
being female and old increase the use of benzodiaze-
pines [16,17]. Studies of illegal use of benzodiazepines in
acute psychiatric admissions are few and the authors
found no studies comparing legal and illegal use at
admittance.
The aims of the present study were to assess the fre-
quency of use of legal and illegal benzodiazepines at admis-
sions to an acute psychiatric department and to compare
patients using legal, illegal and no benzodiazepines.
Methods
Setting
The psychiatric acute department at Østmarka, St.
Olav’s University Hospital Trondheim, Norway had a
catchment area of 140.000 inhabitants. About 700
patients above 18 years with acute psychiatric conditions
were admitted each year. All patients in the catchment
area suffering from acute psychiatric conditions with
symptoms to a degree that locked in-patient ward was
needed, were admitted to this department. Norwegian
acute psychiatric services are public and available to
everyone.
Material
All acute admissions to inpatient treatment in a five
month period were included. If patients were admitted
more than once, all admissions were included.
At admission the patients were systematically asked
about use of prescribed and non-prescribed psychotro-
pic medication. All medications used before admission
and still being prescribed at the time of admission were
recorded. Benzodiazepine derivates sold for oral use in
Norway were diazepam, oxazepam, alprazolam, clonaze-
pam, flunitrazepam and nitrazepam. Zopiclone and zol-
pidem were categorized as non- benzodiazepine
hypnotics. Use of benzodiazepines without a prescrip-
tion is illegal in Norway [18].
The doctor on duty asked all patients at admission if
they had used any substances during the last week. The
doctor on duty also made an assessment whether the
patient were clinically affected by substances or not.
All patients were asked to give urine samples as soon
as possible and samples collected within 24 hours after
admission were included in the study. Findings of sub-
stances used after admissions were not reported. The
samples were analyzed with liquid chromatography with
mass spectrometry (LC-MS). Substances in urine were
reported as present or not present.
Use of substances or medications was defined by
either the patient reported use of substances or medica-
tion during the last week before admission, the medica-
tion was reported used as a prescribed medication, or
the substances or medication were detected in urine
samples at admission. The following psychotropic medi-
cations were recorded: Antiepileptics, lithium, antide-
pressants, sedatives and anxiolytics, antipsychotics,
psychostimulants, methadone and buprenorfin.
Diagnoses according to ICD-10 “Diagnostic criteria for
research” [19] were set at discharge in a weekly consen-
sus meeting in the department’s staff including the
patient’s therapist and at least two psychiatrists of
whom at least one personally knew the patient. In the
present study both main and secondary diagnoses are
reported.
The patients were assessed with the Global Assess-
ment Scale Split version (GAF-S) at admittance [20].
GAF-S is based on DSM-4’sG A Fa n di sat w o - i t e m
scale measuring global symptoms (GAF-S-Symptoms)
and functioning (GAF-S-Function) separately [21].
In the group of patients with psychotic disorders
(ICD-10 F 20.00 - F 29.99) use of antipsychotics in
usual clinical doses for psychoses at admission was
defined as adequate treatment. In patients with affective
disorders (ICD-10 F 30.00 - F39.99) admitted with cur-
rent episode depression, all antidepressants and mood
stabilizing medication were defined as adequate. In
addition atypical antipsychotics was defined as adequate
treatment for patients with bipolar disorder, and all
antipsychotics was defined as adequate treatment of
mania [22].
The admissions were divided in legal use of benzo-
diazepines before admission defined as use of pre-
scribed benzodiazepines, illegal use defined as use of
non prescribed benzodiazepines or a combination of
prescribed and non prescribed benzodiazepines, and
no use of benzodiazepines before admission. Use of
benzodiazepine was considered non-prescribed if there
was no record of prescribed benzodiazepine for the
last year before admission, or if a previous prescription
was terminated by a doctor. New information received
during the stay at hospital was included in the judg-
ment. All written information from the admitting doc-
tor and the hospital staff for the index admission and
admissions from the last year before the index
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group assignment.
Ethics
The study was approved by “The Regional Committee
for Medical Research Ethics, Central Norway”.
Statistics
Categorical variables were analyzed using Chi- squared
test or Fisher’s exact test. Ordinal variables were com-
pared using Mann-Whitney U-test/Kruskal Wallis test,
and continuous variables were analyzed using Students
t-test/ANOVA. Association of frequencies and age
groups was analyzed with the Linear-by-linear associa-
tion test. The a-level was set to 0.05. SSPS version 17.0
for Windows was used.
Results
In the study period 184 patients with 227 admissions
were included. Mean age was 39.5 years (SD 15.5 years).
There were 95 women with 122 admissions and 89 men
with 105 admissions.
There was legal use of benzodiazepines before admission
in 89 (39%) of 227 admissions, illegal use in 30 (13%)
admissions, 9 of these combined legal and illegal benzodia-
zepines, and no use in 108 (48%) admissions. Patients with
legal use of benzodiazepines were older, used more often
antidepressants and a higher number of prescribed psycho-
tropic medications than the rest of the patients (Table 1).
In 65 of 104 (62.5%) admissions with psychoses or major
affective disorders (ICD-10 F 20.00 - 39.99), the patients
received adequate medication with antipsychotics, antide-
pressants or mood stabilizers before admission. Among
the 65 patients receiving adequate medication, 34 (52%)
used benzodiazepines while among the 39 patients that
did not receive adequate medication 11 (28%) used benzo-
diazepines. (c
2 =5 . 7 7 ,d f=1 ,p=0 . 0 1 6 ) .
Legal users had a higher number of prescribed psy-
chotropic medications not including benzodiazepines
than no users (Table 1). Patients with psychoses or
major affective disorders (ICD-10 F 20.00-39.00) treated
with adequate medication, received a higher number of
psychotropic medications not including benzodiazepines
than patients without adequate medication (mean 1.91
(SD 0.861) vs. 0.33 (SD 0.621), p < 0.001) (Mann-Whit-
ney U Test).
Illegal users of benzodiazepines more often used illegal
opiates, cannabis and illegal psychostimulants, and were
often evaluated as clinically affected by a substance at
admittance (Table 2). The illegal users were also more
often diagnosed with a substance use disorder (15/30
(50%) vs. 57/197 (29%), c
2 =5 . 3 3 ,d f=1 ,p=0 . 0 2 ,a
benzodiazepine use disorder (10/30 (33%) vs. 8/197 (4%)
(Fisher’s Exact test P < 0.001) and with a substance use
disorder as the main diagnosis (10/30 (33%) vs. 16/197
(8%), c
2 = 16.3, df = 1 p < 0.001). The frequency of ben-
zodiazepine use disorders in legal users of benzodiaze-
pine was 9% (8/89).
Urine samples were given in 196 of 227 admissions
(86%). The results are summarized in Table 2. The cor-
relations between verbal reports of the patients and
urine analyses are published previously [13]. In the ben-
zodiazepine group 4 patients (3%) had denied use but
tested positive.
Average score for GAF for all admissions was 38.2 for
symptoms and 39.0 for funct i o n ,w i t hn od i f f e r e n c e s
between legal, illegal and no users of benzodiazepines.
Legal use increased with age (Linear-by-linear associa-
tion test, P < 0.001), and 80% of patients 65 years and
older used benzodiazepines at admittance. Illegal use
Table 1 Use of psychotropic medications for patients using legal, illegal and no benzodiazepines.
Legal
(n = 89)
Illegal
(n = 30)
No
(n = 108)
All
(n = 227)
P
Demographics
Women
1 (%) 56 (63) 16 (53) 50 (46) 122 (54) Ns
Age
2 45.1 35.5 36.0 39.5 <0.001
Use of medications
Antipsychotics
1 (%) 31 (35) 4 (13) 31 (29) 66 (29) Ns
Antidepressants
1,3 (%) 34 (38) 10 (33) 23 (21) 67 (30) 0.031
Mood stabilizers
1 (%) 12 (13) 4 (13) 9 (8) 25 (11) Ns
Number of prescribed psychotropic medications, not including benzodiazepines
4 1.58 1.17 0.96 1.23 <0.001
1Chi-square test with 95% confidence intervals computed for each square if Chi-square test is significant.
2One-Way ANOVA test with Post Hoc Tamhane’s tests, legal users were older than no users (P < 0.001) and older than illegal users (P = 0.004).
3No users of benzodiazepines used less antidepressants than legal users.
4Kruskal-Wallis tests with Post Hoc Mann- Whitney U tests, legal users used more other psychiatric medications than no users (p < 0.001).
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association test, P = 0.047) (Figure 1).
A somatic disease had been diagnosed in 73 admis-
sions (32%). These were diseases of the nervous system
(ICD-10 G00-G99) in 28 admissions, diseases of the cir-
culatory system (I00-I99) in 25, diseases of the endo-
crine and metabolic system (E00-E90) in 17, diseases of
the digestive system (K00-K93) in 6, diseases of the
respiratory system (J00-J99) in 5 and various diseases in
18 admissions.
Discussion
Patients admitted to psychiatric acute departments using
benzodiazepines could be divided in two main groups.
Illegal users were young, reported use of multiple illegal
substances and were regarded as clinically affected by
substances at admittance by the doctor on duty. Legal
users were older, did not use multiple substances and
were not regarded as clinically affected by substances at
admittance. Among the illegal users, more than one
benzodiazepine was frequent and the patients often had
Table 2 Reported use of substances, doctor’s evaluation and findings in urine samples
1 at admission
Legal (n = 89) Illegal (n = 30) No (n = 108) All (n = 227) P
Patient report
Use of alcohol last week
2 (%) 29 (33) 15 (50) 49 (45) 93 (41) Ns
Use of illegal opiates last week
3 (%) 3 (3) 7 (23) 0 (0) 10 (4) <0.001
Use of cannabis last week
2 (%) 2 (2) 9 (30) 8 (7) 19 (8) <0.001
Use of illegal stimulants last week
3 (%) 1 (1) 5 (17) 4 (4) 10 (4) 0.004
Doctor’s assessment
Patient regarded clinically affected by a substance
3 (%) 17 (19) 11 (37) 7 (6) 35 (15) <0.001
Urine samples
2 n = 75 n = 30 n = 91 n = 196 Ns
Ethanol in urine
3 (%) 4 (4) 2 (7) 5 (5) 11 (5) Ns
Illegal opiates in urine
3 (%) 3 (3) 5 (17) 2 (2) 10 (4) 0.015
Cannabis in urine
2 (%) 6 (7) 7 (23) 7 (6) 20 (9) 0.036
Illegal stimulants in urine
3 (%) 0 (0) 5 (17) 4 (4) 9 (4) 0.001
Two or more benzo diazepines in urine sample
2 (%) 9 (10) 10 (33) - 19 (8) <0.001
Values higher or lower than expected are marked with bold or underlined italics, respectively.
1Urine samples analyzed with the LC-MS method.
2Chi-square test with 95% confidence interval computed for each square if Chi-square test is significant.
3Fisher’s Exact test with 95% confidence interval computed for each square if Fisher’s Exact test is significant.
Figure 1 Use of legal and illegal benzodiazepines at admission for 227 admissions to an acute psychiatric department.
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were supported by the results from the laboratory tests.
In 62.5% of admissions with psychoses or major affec-
tive disorders the patients had received adequate medi-
cations before admission. Adequate medications were
combined with benzodiazepines in 34 of 65 admissions
while only 11 of 39 patients without adequate medica-
tion prior to admission received benzodiazepines. This
indicates that patients with psychoses or affective disor-
ders in risk of being admitted to psychiatric emergency
departments are treated with benzodiazepines to relieve
acute symptoms as long as the patients display symp-
toms sufficient for their psychiatric conditions to be
diagnosed [2].
The major clinical challenge emerging from the pre-
sent study is the relatively large population not receiving
neither specific nor nonspecific pharmacological treat-
ments before admission. This indicates that many acute
major psychiatric episodes were neither recognized nor
diagnosed before the acute emergency situation brought
the patients to the acute department.
The use of antidepressants was lower among no users
than among legal users of benzodiazepines (Table 1).
We can not exclude the possibility that antidepressants
induce adverse symptoms as agitation in sensitive indivi-
duals leading to more use of benzodiazepines [23,24].
A g i t a t i o ni sc o m m o ni ns e v e r ed e p r e s s i o n( 4 0-7 0 % )
[23] and is a frequent cause of admittance to psychiatric
emergency facilities [25]. Benzodiazepines are effective
and safe in the treatment of agitation [26]. Our data
therefore supports that use of benzodiazepines in our
present acute population could be clinically well-funded.
The doctors were able by the clinical examination at
admittance to indicate which patients were abusing ben-
zodiazepines, and which patients were using benzodiaze-
p i n e sa san o n s p e c i f i c ,s p e c ific or adjuvant medication
as part of the treatment of a major psychiatric disorder.
The legal users were less often regarded as intoxicated
than the illegal users. When using benzodiazepines as
adjuvant treatment for major psychiatric disorders the
need for such treatment would decline as specific treat-
ment with antipsychotics, antidepressants or mood sta-
bilizers have effect on the main disorder. The
probability of long time negative consequences of using
b e n z o d i a z e p i n e sa sp a r to fa na d d i c t i o nh a b i ti sl e s s
among the legal than the illegal users.
This study has limitations. “Doctor’se v a l u a t i o n s ”
reflects the opinion of the experienced clinicians. We do
not have data on how many patients have long-term use
of benzodiazepines.
The present study is strengthened by the prospective
design. All patients from a defined catchment area in
need of acute psychiatric services were included.
Laboratory tests were taken shortly after admittance to
the acute department.
Conclusions
The patients admitted to psychiatric acute departments
using benzodiazepines can be divided in two main
groups. Illegal users were young, used multiple illegal
substances and were often evaluated as clinically affected
by substances at admittance. Legal users were older, did
not use illegal substances and were less frequently evalu-
ated as clinically affected by substances at admittance.
Benzodiazepines were often used as adjuvants to specific
pharmacological treatment with antidepressants, antipsy-
chotics or mood stabilizers for major psychiatric
disorders.
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